Literature DB >> 8797534

Mesial atrophy and outcome after amygdalohippocampectomy or temporal lobe removal.

F Arruda1, F Cendes, F Andermann, F Dubeau, J G Villemure, M Jones-Gotman, N Poulin, D L Arnold, A Olivier.   

Abstract

We studied 74 consecutive patients with temporal lobe epilepsy who were treated surgically and in whom the volumes of mesial temporal structures were determined preoperatively by magnetic resonance imaging. We divided the patients into three groups according to the volumetric findings: unilateral (63.5% of the patients), bilateral (23%), or no atrophy (13.5%) of the amygdala-hippocampal formation. Two distinct surgical approaches were used: selective amygdalohippocampectomy (n = 37) or anterior temporal lobe resection (n = 37). Outcome was assessed at least 1 year after surgery, according to Engel's modified classification. Patients with unilateral mesial temporal atrophy had significantly better results compared with the other two groups (p < 0.001): We found excellent results (class I or II outcome) in 93.6% of the patients with unilateral atrophy, in 61.7% of those with bilateral atrophy, and in 50% of the group with no significant atrophy of mesial temporal structures. The two different surgical techniques were equally effective, regardless of the pattern of atrophy. In conclusion, magnetic resonance volumetric studies in temporal lobe epilepsy proved to be an important preoperative prognostic tool for surgical treatment, but they did not provide guidance for selecting one surgical approach compared to the other.

Entities:  

Mesh:

Year:  1996        PMID: 8797534     DOI: 10.1002/ana.410400314

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  27 in total

1.  Complex Partial Seizures: Surgical Treatment.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-09       Impact factor: 3.598

2.  Complex Partial Seizures in Adults.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-09       Impact factor: 3.598

Review 3.  Neuroimaging of epilepsy.

Authors:  Fernando Cendes; William H Theodore; Benjamin H Brinkmann; Vlastimil Sulc; Gregory D Cascino
Journal:  Handb Clin Neurol       Date:  2016

4.  Predictive value of hippocampal MR imaging-based high-dimensional mapping in mesial temporal epilepsy: preliminary findings.

Authors:  R E Hogan; L Wang; M E Bertrand; L J Willmore; R D Bucholz; A S Nassif; J G Csernansky
Journal:  AJNR Am J Neuroradiol       Date:  2006 Nov-Dec       Impact factor: 3.825

5.  Surgery for epilepsy.

Authors:  Siobhan West; Sarah J Nevitt; Jennifer Cotton; Sacha Gandhi; Jennifer Weston; Ajay Sudan; Roberto Ramirez; Richard Newton
Journal:  Cochrane Database Syst Rev       Date:  2019-06-25

6.  Diagnosis of mesial temporal sclerosis: sensitivity, specificity and predictive values of the quantitative analysis of magnetic resonance imaging.

Authors:  Ana María Granados Sánchez; Juan Felipe Orejuela Zapata
Journal:  Neuroradiol J       Date:  2017-09-13

7.  Referral pattern for epilepsy surgery after evidence-based recommendations: a retrospective study.

Authors:  Zulfi Haneef; John Stern; Sandra Dewar; Jerome Engel
Journal:  Neurology       Date:  2010-08-24       Impact factor: 9.910

8.  Shape analysis of hippocampal surface structure in patients with unilateral mesial temporal sclerosis.

Authors:  R E Hogan; R D Bucholz; I Choudhuri; K E Mark; C S Butler; S Joshi
Journal:  J Digit Imaging       Date:  2000-05       Impact factor: 4.056

9.  Lesional mesial temporal lobe epilepsy and limited resections: prognostic factors and outcome.

Authors:  H Clusmann; T Kral; E Fackeldey; I Blümcke; C Helmstaedter; J von Oertzen; H Urbach; J Schramm
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-11       Impact factor: 10.154

10.  Presurgical connectome and postsurgical seizure control in temporal lobe epilepsy.

Authors:  Leonardo Bonilha; Joseph A Helpern; Rup Sainju; Travis Nesland; Jonathan C Edwards; Steven S Glazier; Ali Tabesh
Journal:  Neurology       Date:  2013-10-09       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.